Production & Manufacturing
Today in Production & Manufacturing

Production & Manufacturing

EMA to review Teva's MAA for migraine prevention drug fremanezumab Teva Pharmaceutical Industries' marketing authorization application (MAA) for fremanezumab has been accepted by the European Medicines Agency (EMA) for the prevention of episodic and chronic migraine in adults. Production & Manufacturing > Process & Production > News

Latest Production & Manufacturing News by Sector

Select a sector from the list or browse by sector below:

Fine & Speciality Chemicals

Bayer plans to focus entirely on Life Science businesses
Bayer intends in the future to focus entirely on the Life Science businesses – HealthCare and CropScience – and float MaterialScience on the stock market as a separate company. In this way Bayer is positioning itself as a world-leading company in the field of human, animal and plant health.
Production & Manufacturing > Fine & Speciality Chemicals > News
CordenPharma agrees to purchase Peptisyntha from Solvay
By PBR Staff Writer
International Chemical Investors Group (ICIG) and the Solvay Group have embarked on an agreement, whereby ICIG will purchase Belgium-based Peptisyntha SA, a custom manufacturer of peptides for pharmaceutical use.
Production & Manufacturing > Fine & Speciality Chemicals > News

Process & Production

EMA to review GW Pharmaceuticals' MAA for antiepileptic drug Epidiolex
The European Medicines Agency (EMA) has accepted for review GW Pharmaceuticals' marketing authorization application (MAA) for Epidiolex (cannabidiol) for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
Production & Manufacturing > Process & Production > News
EMA to review Teva's MAA for migraine prevention drug fremanezumab
By PBR Staff Writer
Teva Pharmaceutical Industries' marketing authorization application (MAA) for fremanezumab has been accepted by the European Medicines Agency (EMA) for the prevention of episodic and chronic migraine in adults.
Production & Manufacturing > Process & Production > News

OTC

Valeant to divest iNova Pharmaceuticals for $930m
By PBR Staff Writer
Valeant Pharmaceuticals International has agreed to divest its iNova Pharmaceuticals business for around $930m.
Production & Manufacturing > OTC > News
Fresenius Kabi agrees to acquire Akorn for $4.3bn
By PBR Staff Writer
German healthcare firm Fresenius Kabi has agreed to acquire US prescription and over-the-counter (OTC) pharmaceutical products manufacturer Akorn for around $4.3bn.
Production & Manufacturing > OTC > News

Manufacturing

Vertex’s Symdeko cystic fibrosis drug secures FDA approval
By PBR Staff Writer
Vertex Pharmaceuticals’ Symdeko (tezacaftor/ivacaftor and ivacaftor) has been approved in the US to treat the underlying cause of cystic fibrosis (CF) in people aged 12 and over.
Regulatory Affairs > News
ViiV Healthcare sues Gilead over HIV drug patent infringement
By PBR Staff Writer
ViiV Healthcare has filed a lawsuit against Gilead Sciences alleging that bictegravir contained in the latter’s triple combination HIV drug infringes patent covering dolutegravir in the US and Canada.
Regulatory Affairs > News